ClinicalTrials.gg
CompletedNCT02588612Updated Sep 5, 2021Results posted

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of letetresgene autoleucel (GSK3377794) and Cyclophosphamide in Neoplasms, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-05.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
42nd of 47
10 · median 88
Started
2016
with 3 others
Phase 1
17 of 54
none open now
Registered
34th of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 42nd largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2016, is one of 17 in phase 1, and was the 34th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.

Read the detailed description

New York esophageal antigen-1 (NY-ESO-1) and L antigen family member (LAGE)-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor engineered TCR T-cells. This protocol investigates letetresgene autoleucel treatment in Human Leukocyte Antigen (HLA)*-A*02+ participants with NY-ESO1+ advanced metastatic non-small cell lung cancer as second line treatment.

03

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Letetresgene autoleucel
  • Adoptive TCR T-cell therapy
  • NY-ESO-1
  • T Cell Receptor
  • Non-Small Cell Lung Cancer
  • Leukapheresis
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 10 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is >=18 years of age on the day of signing .
  • Participant has a diagnosis of or cytologically confirmed advanced non-small cell lung cancer (Stage IIIB or IV) or recurrent disease.
  • Participants with known epidermal growth factor receptor (EGFR) mutations or Anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (disease progression [PD] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity). There is no limit to lines of prior anti-cancer therapy.
  • Participant has according v1.1 criteria.
  • Participant is HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive.
  • Participant's tumor is positive for NYESO and/or LAGE-1a expression by a designated central laboratory.
  • Participant has (ECOG) Performance Status 0-1.
  • Participant has an anticipated >3 months.
  • Participant has >=50 percent(%).
  • Participant is fit for leukapheresis and has adequate venous access for the cell collection.
  • Male or Female. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Participant must have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver or otherwise stable chronic liver disease per Investigator assessment).
  • for prior radiotherapy and chemotherapy and other systemic therapy must be followed.
  • Experimental anti-cancer vaccine within 2 months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months prior to leukapheresis.
  • Any prior gene therapy using an integrating vector.
  • Toxicity from previous anti-cancer therapy that has not recovered to less than or equal to (\<=)Grade 1 prior to enrollment (with exceptions).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.
  • Central nervous system (CNS) metastases.
  • Active or .
  • History of chronic or recurrent (within the last year prior to enrollment) severe or active immune-mediated disease requiring or other treatments.
  • Other active besides NSCLC within 3 years prior to Screening not in complete remission.
  • Unintended weight loss >10% in 6 months preceding study entry.
  • interval (QTc) >450 milliseconds (msec) or QTc >480 msec for participants with Bundle Branch Block (BBB).
  • Uncontrolled intercurrent illness.
  • Participants who in the opinion of the Investigator will be unlikely to fully comply with protocol requirements.
  • Active infection with (HIV), virus (HBV), virus (HCV) or human T-cell lymphotropic virus (HTLV).
  • Participant is pregnant or breastfeeding.
  • Major surgery within 4 weeks prior to lymphodepleting chemotherapy.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    letetresgene autoleucel (GSK3377794)

    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.

    Drug: letetresgene autoleucel (GSK3377794) · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

07

What researchers measure

Primary outcomes

  1. Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is clinically significant or requires intervention to prevent one of the outcomes listed before. Number of participants with common (greater than or equal to \[\>=\]5 percent\[%\]) non-serious AEs and SAEs are presented.

    Time frame: Up to 24 months

  2. Number of Participants With Hematology Results by Maximum Grade Increase Post-Baseline

    Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst-case post-Baseline is presented

    Time frame: Up to 24 months

  3. Number of Participants With Any Grade Increase in Clinical Chemistry Parameters

    Blood samples were collected for analysis of clinical chemistry parameters: glucose (Gl), albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (Bil), creatinine (Creat), potassium (Pot), magnesium (Mg), phosphate (Ph), sodium (Sod) and calcium. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst-case post-Baseline is presented.

    Time frame: Up to 24 months

  4. Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings

    12-lead ECGs were recorded in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings for worst case post-Baseline have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Up to 24 months

  5. Change From Baseline in Oxygen Saturation

    Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen saturation was measured using a pulse oximeter. Baseline is the most recent, non-missing value within 7 days prior to initiating the lymphodepleting chemotherapy. Change from Baseline is the post-Baseline visit value minus Baseline value.

    Time frame: Baseline, Day 1 (pre-dose, 5, 15, and 30 minutes, 1, 1.5, 2, and 4 hours post dose), Days 2, 3, 4, 5, 8 and Week 2

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed Partial response (PR) or Complete response (CR) as the Best overall response (BOR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Confidence Interval (CI) was calculated using the exact method. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters.

    Time frame: Up to 24 Months

  2. Time to Response

    Time to response is defined as the interval of time (in months) between the date of T-cell infusion and the first documented evidence of response (PR or CR) in the subset of participants with a confirmed PR or CR as the BOR as assessed by the investigator per RECIST v1.1.

    Time frame: Up to 24 months

  3. Duration of Response

    Duration of response (DoR), defined as the interval of time in months from first documented evidence of PR or better to the time when disease progression is documented as assessed by RECIST v1.1 or death due to any cause among participants with a confirmed PR or CR as the BOR.

    Time frame: Up to 24 months

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a stable disease (SD) or better as the BOR (Confirmed PR, confirmed CR, or SD \>=12 weeks), as assessed by the investigator per RECIST v1.1. CI was calculated using the exact method.

    Time frame: Up to 24 months

  5. Progression-Free Survival (PFS) by Investigator Assessment

    Progression-free survival (PFS) is defined as the interval of time (in months) between the date of T-cell infusion and the earlier of the date of disease progression as assessed by the investigator and the date of death due to any cause. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Median and inter-quartile range (first quartile and third quartile) are presented.

    Time frame: Up to 24 months

08

Results

Posted Sep 5, 2021

Participant flow

This was an open-label study evaluating the safety and tolerability of autologous T-Cells expressing enhanced T-cell receptors (TCRs) specific for New York esophageal squamous cell carcinoma (NY-ESO)-1 (letetresgene autoleucel, lete-cel, GSK3377794) in Human Leukocyte Antigen (HLA)-A\*02:01, HLA-A\*02:05 and/or HLA-A\*02:06 participants with stage IIIb or stage IV non-small cell lung cancer (NSCLC).

Participant flow — Overall Study
MilestoneLete-cel
Started10
Received t-cell infusion5
Completed5
Not completed5
Withdrew: Physician decision1
Withdrew: Leukapheresis did not yield enough cells1
Withdrew: Failed eligibility prior to chemotherapy2
Withdrew: Death prior to t-cell infusion1

Outcome measures

PrimaryNumber of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is clinically significant or requires intervention to prevent one of the outcomes listed before. Number of participants with common (greater than or equal to \[\>=\]5 percent\[%\]) non-serious AEs and SAEs are presented.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsLete-cel
Non SAEs6
SAEs4
PrimaryNumber of Participants With Hematology Results by Maximum Grade Increase Post-Baseline

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst-case post-Baseline is presented

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Hematology Results by Maximum Grade Increase Post-Baseline
ParticipantsLete-cel
Hemoglobin increased0
Hemoglobin (Anemia)3
Lymphocytes increased1
Lymphocytes decreased5
Neutrophils5
Platelets5
Leukocytes (Leukocytosis)0
Leukocytes (Leukopenia)5
PrimaryNumber of Participants With Any Grade Increase in Clinical Chemistry Parameters

Blood samples were collected for analysis of clinical chemistry parameters: glucose (Gl), albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (Bil), creatinine (Creat), potassium (Pot), magnesium (Mg), phosphate (Ph), sodium (Sod) and calcium. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst-case post-Baseline is presented.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Any Grade Increase in Clinical Chemistry Parameters
ParticipantsLete-cel
Gl, Hyperglycemia2
Gl, Hypoglycemia0
Albumin2
ALP2
ALT3
AST4
Bil1
Creat1
Pot, Hyperkalemia2
Pot, Hypokalemia1
Mg, Hypermagnesemia0
Mg, Hypomagnesemia2
Ph4
Sod, Hypernatremia0
Sod, Hyponatremia1
Calcium, Hypercalcemia1
Calcium, Hypocalcemia3
PrimaryNumber of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings

12-lead ECGs were recorded in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal not clinically significant (NCS) and clinically significant (CS) ECG findings for worst case post-Baseline have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings
ParticipantsLete-cel
Abnormal, NCS2
Abnormal, CS1
PrimaryChange From Baseline in Oxygen Saturation

Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen saturation was measured using a pulse oximeter. Baseline is the most recent, non-missing value within 7 days prior to initiating the lymphodepleting chemotherapy. Change from Baseline is the post-Baseline visit value minus Baseline value.

Time frame:
Baseline, Day 1 (pre-dose, 5, 15, and 30 minutes, 1, 1.5, 2, and 4 hours post dose), Days 2, 3, 4, 5, 8 and Week 2
Reported as:
Median · Percentage of oxygen
Change From Baseline in Oxygen Saturation
Percentage of oxygenLete-cel
Day 1, pre dose, n=52.0 (-2 to 6)
Day 1, 5 minutes post dose, n=42.5 (1 to 3)
Day 1, 15 minutes post dose, n=42.0 (-3 to 5)
Day 1, 30 minutes post dose, n=43.0 (-2 to 3)
Day 1, 1 hour post dose, n=52.0 (-2 to 5)
Day 1, 1.5 hours post dose, n=21.5 (1 to 2)
Day 1, 2 hours post dose, n=33.0 (2 to 5)
Day 1, 4 hours post dose, n=4-1.0 (-3 to 3)
Day 2, n=42.5 (1 to 4)
Day 3, n=51.0 (-1 to 4)
Day 4 , n=51.0 (-3 to 4)
Day 5, n=5-2.0 (-3 to 4)
Day 8, n=40.0 (-1 to 1)
Week 2, n=41.5 (1 to 3)
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed Partial response (PR) or Complete response (CR) as the Best overall response (BOR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Confidence Interval (CI) was calculated using the exact method. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters.

Time frame:
Up to 24 Months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsLete-cel
Overall Response Rate (ORR)20 (0.5 to 71.6)
SecondaryTime to Response

Time to response is defined as the interval of time (in months) between the date of T-cell infusion and the first documented evidence of response (PR or CR) in the subset of participants with a confirmed PR or CR as the BOR as assessed by the investigator per RECIST v1.1.

Time frame:
Up to 24 months
Reported as:
Number · Months
Time to Response
MonthsLete-cel
Time to Response12.09
SecondaryDuration of Response

Duration of response (DoR), defined as the interval of time in months from first documented evidence of PR or better to the time when disease progression is documented as assessed by RECIST v1.1 or death due to any cause among participants with a confirmed PR or CR as the BOR.

Time frame:
Up to 24 months
Reported as:
Number · Months
Duration of Response
MonthsLete-cel
Duration of Response6.18
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants with a stable disease (SD) or better as the BOR (Confirmed PR, confirmed CR, or SD \>=12 weeks), as assessed by the investigator per RECIST v1.1. CI was calculated using the exact method.

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsLete-cel
Disease Control Rate (DCR)20 (0.5 to 71.6)
SecondaryProgression-Free Survival (PFS) by Investigator Assessment

Progression-free survival (PFS) is defined as the interval of time (in months) between the date of T-cell infusion and the earlier of the date of disease progression as assessed by the investigator and the date of death due to any cause. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Median and inter-quartile range (first quartile and third quartile) are presented.

Time frame:
Up to 24 months
Reported as:
Median · Months
Progression-Free Survival (PFS) by Investigator Assessment
MonthsLete-cel
Progression-Free Survival (PFS) by Investigator Assessment1.81 (0.99 to 5.29)

Adverse events

Collected over All-cause mortality, SAEs and common (>=5%) non-serious AEs were collected from the enrollment to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lete-cel4/10 (40%)4/10 (40%)6/10 (60%)
Most frequent serious events
Most frequent serious events
EventLete-cel
Cytokine release syndromeImmune system disorders2/10
PneumoniaInfections and infestations2/10
AnaemiaBlood and lymphatic system disorders1/10
ConstipationGastrointestinal disorders1/10
NauseaGastrointestinal disorders1/10
EncephalopathyNervous system disorders1/10
Haemorrhage intracranialNervous system disorders1/10
Respiratory distressRespiratory, thoracic and mediastinal disorders1/10
Rash maculo-papularSkin and subcutaneous tissue disorders1/10
HypotensionVascular disorders1/10
Most frequent other events
Showing 10 of 58
Most frequent other events
EventLete-cel
Lymphocyte count decreasedInvestigations5/10
White blood cell count decreasedInvestigations5/10
Neutrophil count decreasedInvestigations4/10
Platelet count decreasedInvestigations4/10
AnaemiaBlood and lymphatic system disorders4/10
FatigueGeneral disorders3/10
HeadacheNervous system disorders3/10
Decreased appetiteMetabolism and nutrition disorders3/10
NeutropeniaBlood and lymphatic system disorders2/10
NauseaGastrointestinal disorders2/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lete-cel
Overall study57.7 ± 12.91
Sex: Female, Male
Sex: Female, Male(Participants)Lete-cel
Female4
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lete-cel
Asian1
White9
09

Study locations

3 sites
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Aug 2020, 54 months.

Results were first posted in Sep 2021, 1 year after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 54 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2015
First posted
Oct 28, 2015
StartActual
Feb 1, 2016
Primary completionActual
Aug 10, 2020
CompletionActual
Aug 10, 2020
Results first posted
Sep 5, 2021
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02588612
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Feb 1, 2016
Primary completion
Aug 10, 2020
Completion
Aug 10, 2020
Results posted
Sep 5, 2021
Last update
Sep 5, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letetresgene autoleucel

Start the discussion